What is Xenon Pharmaceuticals's D&A?

Xenon Pharmaceuticals (XENE) reported D&A of $587K in Q1 2026.

How has Xenon Pharmaceuticals's D&A changed year-over-year?

Xenon Pharmaceuticals's D&A decreased by 10.9% year-over-year, from $659K to $587K.

What is the long-term trend for Xenon Pharmaceuticals's D&A?

Over 3 years (2021 to 2025), Xenon Pharmaceuticals's D&A has grown at a 41.1% compound annual growth rate (CAGR), from $906K to $2.54M.

Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.

Xenon Pharmaceuticals XENE D&A

D&A at other companies

Eli LillyLLY

$509M+9.9%

Johnson & JohnsonJNJ

$2B+13.1%

Jazz PharmaceuticalsJAZZ

$9.1M-12.5%

Axsome TherapeuticsAXSM

$116K-22.1%

Praxis Precision Medicines, Inc.PRAX

$39K-17.0%

Neurocrine BiosciencesNBIX

$7.2M+9.1%

Other financials

Income statement

See full

Revenue--100%

Operating income-$112.3M-54.4%

Net income-$102.3M-57.3%

EPS (diluted)-$1.17-41.0%

Balance sheet

See full

Cash & equivalents$545.9M+368%

Total debt$7.5M-13.6%

Total equity$1.3B+90.0%

Total assets$1.4B+86.6%

Cash flow

See full

Operating cash flow-$88.9M-44.2%

CapEx$133.0K+209%

Free cash flow-$89.0M-44.3%

Valuation

See full

Market cap$5.11B+116%

Profitability

See full

Operating margin-4,974.3%—

Net margin-4,612.1%—

FCF margin-3,732.2%—

Returns & leverage

See full

Return on equity-37.5%+8.7pp

Debt / equity0×0.0×

Current ratio27.8×+10.1×

Where this comes from

Reported directly by Xenon Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:DepreciationAndAmortization.

The official record: Xenon Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Xenon Pharmaceuticals's d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Xenon Pharmaceuticals's D&A?: Xenon Pharmaceuticals (XENE) reported D&A of $587K in Q1 2026.
How has Xenon Pharmaceuticals's D&A changed year-over-year?: Xenon Pharmaceuticals's D&A decreased by 10.9% year-over-year, from $659K to $587K.
What is the long-term trend for Xenon Pharmaceuticals's D&A?: Over 3 years (2021 to 2025), Xenon Pharmaceuticals's D&A has grown at a 41.1% compound annual growth rate (CAGR), from $906K to $2.54M.
What does D&A mean?: Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.